Given the dual oncogenic role of CCNB1 in resisting NK cell-mediated killing and enhancing melanoma invasiveness, we propose that CCNB1/CDK1 inhibitors represent a promising strategy to enhance NK cell-based immunotherapy for melanoma. The gene discussed is CCNB1; the disease is melanoma.